The mRNA and protein expression of HO-2 in control group and portal hypertension group was(0.64±0.12) vs(0.58±0.09),(0.84±0.14) vs(0.92±(0.12),) respectively,with the difference being not significant(both P>0.05).
Results The mRNA and protein expression of HO-1 in control group was(0.03±0.00) and(0.04±0.01) respectively,significantly lower than that in portal hypertension group [(0.81±0.12) and(1.56±0.25) respectively,both P<0.01].
Results: The mean level and standard deviation of SAAG of the group associated with portal hypertension and the group without portal hypertension was 18.5 g/L±5.3 g/L, and 7.0 g/L±3.1 g/L, respectively (P<0.001).
Using SAAG≥11 g/L as the cut-off value,the diagnostic sensitivity for ascites associated with portal hypertension was 95.7%,diagnostic specificity was 98.1%,diagnostic accuracy was 96.8%,positive predictive value was 98.5%,negative predictive value was 94.6%.
The portal venous pressure was (17.8±2.9) cm H_2O and (18.3±2.9) cm H_2O before and after PVE. There was statistical difference in portal venous pressure before and after PVE (t=-14.810,P<0.05), but the value was normal. No patient had portal vein hypertension after PVE.
Methods:Twenty four rabbits of portal vein hypertension model,produced by ligating partly the portal vein,weighted from 2 0 to 2 5kg,were randomly divided into control group,sodium nitroprusside (SNP)group and N nitro L arginine methyl ester (L NAME)group with 8 each. After anesthesia with pentobarbital sodium 30mg/kg intravenously,tracheotomy was performed and femoral artery intubation was done to monitor blood pressure.
Conclusion: The morphologic and histologic structure of intestinal mucosa was damaged dramatically after PN support in cirrhotic and portal hypertensive rats, the barrier funtion was also influenced remarkably, while these changes were seldomappeared in EN and EN +PN groups.
Immunohistochemistry and double labeling immunofluo-rescence combined with laser scanning confocal microscope were used to investigate the expression of eNOS ET-1 NF-κB and PKC protein in endothelial cells of splenic veins from portal hypertensive patients (n =20) and portal veins from Wistar rats (n =15).
Results: MSCTP image could directly demonstrate the location and width of the portal and hepatic veins, detect the invasion and tumor thrombosis of portal vein, and show the range of collateral circulation and estimate its degree in portal venous hypertension.
We recognized and honoured the important contributions of these Chinese pioneers in portal hypertension, recurrent pyogenic cholangitis, hepatocellular carcinoma and liver transplantation.
Splenic autotransplantation and oesophageal transection anastomosis in patients with portal hypertension (26 years clinical obse
The surgical treatment methods for cirrhosis patients complicated with portal hypertension are complicated.
From 1979 to 2005, 274 cirrhosis patients with portal hypertension who underwent the new treatment strategy were followed up to observe different clinical indexes, which were then compared with those of the traditional surgery treatment.
Splenic auto transplantation and esophageal transection anastomosis are a safe, effective, and reasonable treatment strategy for portal hypertension with varicial bleeding.
The uses include variceal hemorrhage and ascites as well as miscellaneous indications such as Budd-Chiari syndrome, veno-occulsive disease, bleeding ectopic and rectal varices, hepatic hydrothorax, and portal hypertensive gastropathy.
Other more novel indications include bleeding portal hypertensive gastropathy or ectopic varices, Budd-Chiari syndrome, veno-occlusive disease, hepatorenal syndrome, hepatopulmonary syndrome, hepatocellular carcinoma, and polycystic liver disease.
Portal hypertensive gastropathy and gastric antral vascular ectasia
Portal hypertensive gastropathy (PHG) causes both acute and chronic blood loss from the gastrointestinal tract in patients with portal hypertension.
The classification of cirrhotic liver disease by Child and Turcotte was initially utilized to predict mortality in patients undergoing surgically placed shunts for portal hypertensive bleeding.